The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...

In this webinar, expert panelists discuss the key challenges in complex mAb purification and offer practical solutions to optimize downstream processing systems for even the most complex mAb formats.< ...

HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025Building on ...

SEC asks SII to submit more data for approval of recombinant mAB for dengue treatment in adults: Our Bureau, New Delhi Wednesday, January 29, 2025, 08:00 Hrs [IST] The Subject Exp ...

Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Adagene in a research note issued to investors on Monday, January 27th. HC Wainwright analyst A. He anticipates that the ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...